ORPHAN DRUG EXCLUSIVITY WAIVER AGREEMENTOrphan Drug Exclusivity Waiver Agreement • August 6th, 2007 • Medarex Inc • Services-commercial physical & biological research
THIS ORPHAN DRUG EXCLUSIVITY WAIVER AGREEMENT (the “Agreement”) is entered into as of April 25, 2007 (the “Effective Date”) by and between Pfizer Inc, a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017 (“Pfizer”), Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”) and Medarex, Inc., a New Jersey corporation with a business address at 707 State Road, Princeton, NJ 08540 (“Medarex”). Pfizer, BMS and Medarex each may be referred to herein individually as a “Party” or collectively as the “Parties.”
